USO 24257

A Randomized Open-Label Phase 2/3 Study of Datopotamab-Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed during or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment - DS1062-328

Disease Types: Genitourinary Cancer Research

Eligibility Requirements:

• Histologically or cytologically confirmed unresectable locally
advanced or metastatic urothelial carcinoma of the bladder,
renal pelvis, ureter, or urethra
• Subjects must be considered eligible to receive cisplatin- or
carboplatin-containing therapy
• Must have experienced radiographic progression or relapse
during or after 1L of EV/pembrolizumab
• Subjects that received prior therapy other than
EV/pembrolizumab combo are excluded
• Subjects with history of allogenic transplant or prior TROP2
directed ADC therapy are excluded

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg